# LiGeR - HN1 (NCT06525220)

> A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06525220
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merus B.V.
- Conditions: Head and Neck Squamous Cell Carcinoma
- Interventions: Petosemtamab; Pembrolizumab
- Enrollment: 699
- Primary outcome: Overall Survival (OS)
- Primary outcome: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review (BICR)

## Indexed commentary on LiGeR - HN1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 2
- X threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=liger-hn1-nct06525220